ArticleClinical & experimental metastasis2025
TEAD4 promoted proliferation and metastasis of gallbladder cancer by regulation of TMPRSS4.
Article in Clinical & experimental metastasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer (GBC) is an aggressive malignancy with a poor prognosis, often diagnosed at advanced stages. TEA domain transcription factor 4 (TEAD4) has been implicated in mediating the progression of various cancers, but its function and underlying mechanism in gallbladder cancer remain unclear. This study assessed the expression levels of TEAD4 and TMPRSS4 using reverse transcription quantitative polymerase chain reaction and western blotting. The functional role of TEAD4 in the progression of gallbladder cancer was investigated through CCK-8, EdU assays, Transwell, wound-healing assays, western blotting, immunohistochemistry, and hematoxylin and eosin (H&E) staining in cellular and animal models. The potential regulatory mechanism was explored by chromatin immunoprecipitation and dual-luciferase reporter assays. Results revealed that TEAD4 expression was significantly elevated in GBC tissues and cell lines. TEAD4 knockdown suppressed cell viability, decreased the percentage of EdU-positive cells, reduced invasive capacity, and increased wound closure width in GBC-SD and NOZ cells. Conversely, overexpression of TEAD4 produced opposite effects. Mechanistically, TEAD4 was predicted and confirmed to bind with the promoter region of TMPRSS4, as validated by the Chip-PCR and dual luciferase results. The mitigatory role of sh-TEAD4 on cell growth, invasion, and mobility of GBC was reversed by overexpression TMPRSS4 overexpression. In vivo, silencing of TEAD4 declined the tumor size and weight, the expression of TEAD4 and TMPRSS4, the ki-67 level, and the numbers of liver metastasis foci. In conclusion, the knockdown of TEAD4 suppressed the growth and metastasis of GBC via TMPRSS4.
Indexed as
Identifiers
40214821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.